5-Amino 1MQ
PEPTIDES+ MEMBERS ONLY
INDICATIONS FOR USE
5-Amino 1MQ is used off-label and experimentally in the context of weight management, metabolic optimization, and potential anti-aging support. It may support fat loss, insulin sensitivity, and healthy cellular energy metabolism. It is often used in conjunction with lifestyle interventions to aid in body recomposition or glucose regulation.
ROUTE OF ADMINISTRATION
Oral capsule
FORMULATIONS AND PRICING
| Formulation | Price |
|---|---|
| 50mg Oral Capsules (#30) | $120 |
| 50mg Oral Capsules (#60) | $225 |
| 50mg Oral Capsules (#90) | $315 |
COMMON INITIAL DOSING REGIMENS
A typical starting dose is 50–100 mg taken orally once daily. Doses may be increased to twice daily based on patient response and tolerance. Treatment cycles often range from 4 to 12 weeks.
MECHANISM OF ACTION
5-Amino 1MQ is a small molecule inhibitor of NNMT (Nicotinamide N-methyltransferase), an enzyme involved in energy metabolism, adipogenesis, and epigenetic regulation. By inhibiting NNMT, 5-Amino 1MQ may enhance cellular NAD+ availability and promote increased metabolic rate and fat oxidation. In animal models, NNMT inhibition has been associated with decreased fat mass and improved insulin sensitivity.
COMMON SIDE EFFECTS
General: Mild headache, nausea, or jitteriness during initial dosing.
Metabolic: Possible changes in appetite or thirst, especially in conjunction with calorie restriction.
Neurologic: Rare reports of insomnia or increased alertness.
Rare: Elevated blood pressure or gastrointestinal discomfort.
CONTRAINDICATIONS
Absolute: Known hypersensitivity to 5-Amino 1MQ or its components.
Relative: Use with caution in individuals with uncontrolled hypertension, hyperthyroidism, or active cardiac disease due to potential sympathomimetic effects. Not recommended during pregnancy or breastfeeding.
COMPARISON WITH OTHER AGENTS
Semaglutide or Tirzepatide: These GLP-1 receptor agonists are FDA-approved for weight loss and act via appetite suppression and delayed gastric emptying. 5-Amino 1MQ differs by working primarily on cellular metabolism and fat oxidation, not appetite.
NAD+ Precursors: 5-Amino 1MQ increases NAD+ indirectly by limiting its breakdown, whereas NMN or NR increase NAD+ via direct precursor supplementation.
Cagrilintide: Another weight loss agent with appetite-suppressing effects, Cagrilintide acts centrally on satiety pathways, while 5-Amino 1MQ modulates cellular energy metabolism.
EXPERIMENTAL TREATMENT DISCLAIMER:
5-Amino 1MQ is not approved by the FDA for the treatment, mitigation, or prevention of any disease. Its use is considered experimental. While early research and anecdotal evidence suggest potential benefits, the long-term safety and efficacy of 5-Amino 1MQ in humans have not been established. By proceeding with treatment, the patient acknowledges the experimental nature of this therapy and accepts full responsibility for its use.
MORE INFORMATION
FDA Safety Data Sheet not available (experimental peptide).